Antitrust Antitrust

US drug prices have increased through product-hopping, other patent abuse, House committee report says

By Max Fillion
  • 10 Dec 2021 12:40
  • 10 Dec 2021 13:27
Pharmaceutical companies have juiced US drug prices through a series of anticompetitive tactics, including product-hopping and other patent abuses that extend branded drugs’ market exclusivity periods, a staff report released today by a House committee says.

The report (see here) caps a three-year investigation by the US House Committee on Oversight and

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News